Skip to main content

Table 3 IMPDH1 expression

From: Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study

  

Treatment group

Total

IMPDH1

Week

Belatacept (n = 4)

Cyclosporine (n = 3)

 

E0

0

0.63

(0.54–0.76)

0.44

(0.37–0.79)

0.59

(0.37–0.79)

 

1

0.56

(0.32–1.1)

0.75

(0.67–0.75)

0.67

(0.32–1.1)

 

2

0.45

(0.17–0.54)

0.54

(0.43–0.62)

0.50

(0.17–0.62)

 

13

0.42

(0.25–0.59)

0.31

(0.30–0.43)

0.36

(0.25–0.59)

AUC0–9 h

(% of E0 × h)

1

1018

(866–1128)

794

(736–881)

880

(736–1128)

 

2

1146

(781–1278)

784

(741–1146)

1145

(741–1622)

 

13

1070

(911–1201)

1291

(1193–1540)

1197

(911–1540)

Emin

(% of E0)

1

85.3

(75.3–115)

69.3

(46.8–92.2)

82.0

(46.8–115)

 

2

94.4

(80.2–103)

71.1

(60.7–94.3)

87.3

(60.7–103)

 

13

97.0

(57.2–99.6)

113

(89.5–117)

98.3

(57.2–117)

Emax (% of E0)

1

140

(108–143)

105

(102–122)

121

(102–143)

 

2

147

(105–189)

107

(104–151)

127

(104–189)

 

13

161

(133–196)

203

(173–222)

185

(133–222)

  1. Data are given as median (range). The belatacept group includes 3 patients at week 13 and for the maximum, minimum and AUC calculations at week 2. E0, predose expression; Emax, maximum expression; Emin, minimum expression; AUC, area under the variable versus time curve.